Review Article | Published:

The role of vitamin D in reducing cancer risk and progression

Nature Reviews Cancer volume 14, pages 342357 (2014) | Download Citation

Abstract

Vitamin D is not really a vitamin but the precursor to the potent steroid hormone calcitriol, which has widespread actions throughout the body. Calcitriol regulates numerous cellular pathways that could have a role in determining cancer risk and prognosis. Although epidemiological and early clinical trials are inconsistent, and randomized control trials in humans do not yet exist to conclusively support a beneficial role for vitamin D, accumulating results from preclinical and some clinical studies strongly suggest that vitamin D deficiency increases the risk of developing cancer and that avoiding deficiency and adding vitamin D supplements might be an economical and safe way to reduce cancer incidence and improve cancer prognosis and outcome.

Key points

  • Vitamin D3 is the precursor to the potent steroid hormone calcitriol (1,25 dihydroxyvitamin D3 (1,25(OH)2D3)) that regulates the expression of many genes in most tissues of the body.

  • Dietary vitamin D3 is converted into 25 hydroxyvitamin D3 (25(OH)D3) in the liver; this is the circulating form of vitamin D, which is subsequently hydroxylated to form calcitriol by the cytochrome P450 enzyme CYP27B1 in the kidneys. Calcitriol is also synthesized locally by CYP27B1 present in most extrarenal tissues, including many cancer cells, where it acts in a paracrine manner. Levels of calcitriol are additionally regulated by the cytochrome P450 enzyme CYP24A1, which begins the inactivation of calcitriol through 24-hydroxylation.

  • Calcitriol regulates multiple signalling pathways involved in proliferation, apoptosis, differentiation, inflammation, invasion, angiogenesis and metastasis, and it therefore has the potential to affect cancer development and growth. Recent findings indicate that calcitriol also regulates microRNA expression and may affect cancer stem cell biology.

  • Multiple cell culture and animal models of cancer support a role for dietary vitamin D3 and calcitriol in retarding cancer development and progression; however, data from human clinical trials are thus far inconsistent.

  • Epidemiological studies suggest that vitamin D deficiency is associated with increased incidence of cancer and worse outcomes, although many studies do not demonstrate these associations.

  • Single nucleotide polymorphisms (SNPs) in the vitamin D receptor (VDR) and vitamin D3 synthesis and degradation pathways have been implicated in affecting the risk of cancer development.

  • Given the interest in using vitamin D3 to reduce cancer risk, further research is needed, particularly randomized controlled trials (RCTs), to demonstrate in humans whether individuals with low levels of circulating 25(OH)D are at increased risk of developing cancer and whether calcitriol or vitamin D supplements can reduce cancer risk and progression and improve outcomes.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & Current progress in using vitamin D and its analogs for cancer prevention and treatment. Expert Rev. Anticancer Ther. 12, 811–837 (2012). This is an extensive and detailed review of the vitamin D hypothesis for cancer prevention and treatment.

  2. 2.

    & Vitamin D and differentiation in cancer. Crit. Rev. Clin. Lab Sci. 46, 190–209 (2009).

  3. 3.

    & Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu. Rev. Pharmacol. Toxicol. 51, 311–336 (2011).

  4. 4.

    , & Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J. Steroid Biochem. Mol. Biol. 121, 343–348 (2010).

  5. 5.

    , , & The role of vitamin D in cancer prevention and treatment. Endocrinol. Metab. Clin. North Am. 39, 401–418 (2010). This is a recent review of the evidence for and against the role of vitamin D in the prevention and treatment of cancer.

  6. 6.

    , & Antineoplastic effects of 1,25(OH)2D3 and its analogs in breast, prostate and colorectal cancer. Endocr. Relat. Cancer 20, R31–R47 (2013).

  7. 7.

    , , , & Vitamin D and breast cancer: Emerging concepts. Cancer Lett. 334, 95–100 (2013).

  8. 8.

    , & Vitamin D and colon cancer. Endocr. Relat. Cancer 19, R51–R71 (2012). This is a recent review of the mechanism of action of calcitriol and the evidence for a role of vitamin D in the prevention and treatment of colon cancer.

  9. 9.

    et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr. Rev. 33, 456–492 (2012). This paper contains the opinions of an expert committee appointed by the Endocrine Society to evaluate the role of vitamin D in non-skeletal actions and diseases.

  10. 10.

    et al. Vitamin D in cutaneous carcinogenesis: part II. J. Am. Acad. Dermatol. 67, 817 (2012).

  11. 11.

    & The vitamin D receptor in cancer. Proc. Nutr. Soc. 67, 115–127 (2008).

  12. 12.

    , & Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 16, 1–9 (2010).

  13. 13.

    Cellular and molecular effects of vitamin D on carcinogenesis. Arch. Biochem. Biophys. 523, 107–114 (2012).

  14. 14.

    , & Vitamin D (Elsevier Academic Press, 2011). This is a multi-authored two-volume tome, which covers all aspects of vitamin D synthesis, metabolism, mechanism of action and clinical applications, with a large section of the book devoted to the effects of vitamin D on multiple cancers. Each of the many chapters is written by acknowledged experts in their areas.

  15. 15.

    Vitamin D deficiency. N. Engl. J. Med. 357, 266–281 (2007). This is an extensive review of vitamin D synthesis, metabolism and action, with a focus on the causes and extent of worldwide vitamin D deficiency.

  16. 16.

    , & in Osteoporosis (eds Marcus, R., Feldman, D., Dempster, D., Luckey, M. & Cauley, J.) 283–329 (Elsevier Academic Press, 2013).

  17. 17.

    Institute of Medicine Report. Dietary Reference Intakes for Calcium and Vitamin D. (Institute of Medicine, 2011). This is the full IOM report that details a large number of studies regarding vitamin D deficiency and daily requirements. The report deals with the evidence for and against a role for vitamin D in skeletal and non-skeletal diseases and gives guidelines for establishing cut-off points for vitamin D deficiency.

  18. 18.

    et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911–1930 (2011). These are the Endocrine Society guidelines, which differ in some respects from the IOM conclusions.

  19. 19.

    , & Cytochrome P450-mediated metabolism of vitamin D. J. Lipid Res. 55, 13–31 (2014). This is a detailed report on the nature and actions of the crucial enzymes that regulate the synthesis and degradation of vitamin D.

  20. 20.

    & Vitamin D 25-hydroxylase — Four decades of searching, are we there yet? Arch. Biochem. Biophys. 523, 30–36 (2012).

  21. 21.

    et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96, 53–58 (2011). This is a complete summary of the IOM opinion about the daily requirements of vitamin D, the cut-off point for vitamin D deficiency, the incidence of vitamin D deficiency and the opinion of the committee about the evidence for the efficacy of vitamin D in preventing or treating skeletal and non-skeletal diseases.

  22. 22.

    , & Where is the vitamin D receptor? Arch. Biochem. Biophys. 523, 123–133 (2012).

  23. 23.

    et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 29, 726–776 (2008).

  24. 24.

    , & Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Rev. Cancer 7, 684–700 (2007). This is an extensive review of vitamin D signalling pathways.

  25. 25.

    , , & Vitamin D and cancer: a review of molecular mechanisms. Biochem. J. 441, 61–76 (2012).

  26. 26.

    et al. Molecular mechanisms of vitamin D action. Calcif. Tissue Int. 92, 77–98 (2013).

  27. 27.

    in Vitamin D (eds Feldman, D., Pike, J. W. & Adams, J. S.) 43–56 (Elsevier Academic Press, 2011).

  28. 28.

    Vitamin D analogs. Endocrinol. Metab. Clin. North Am. 39, 447–472 (2010).

  29. 29.

    , & Vitamin D in chronic kidney disease. Best Pract. Res. Clin. Endocrinol. Metab. 25, 647–655 (2011).

  30. 30.

    , & Regulation and function of the FGF23/klotho endocrine pathways. Physiol. Rev. 92, 131–155 (2012).

  31. 31.

    , , & Role of calcium, vitamin d, and the extrarenal vitamin d hydroxylases in carcinogenesis. Anticancer Agents Med. Chem. 13, 20–35 (2013).

  32. 32.

    & Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch. Biochem. Biophys. 523, 95–102 (2012). This is an excellent review of the presence and importance of extrarenal CYP27B1 for the extraskeletal actions of vitamin D.

  33. 33.

    et al. Regulation of 25-hydroxyvitamin D-1α-hydroxylase by epidermal growth factor in prostate cells. J. Steroid Biochem. Mol. Biol. 89–90, 127–130 (2004).

  34. 34.

    Regulation of intracrine production of 1,25-dihydroxyvitamin D and its role in innate immune defense against infection. Arch. Biochem. Biophys. 523, 58–63 (2012).

  35. 35.

    et al. The prostate 25-hydroxyvitamin D-1 α-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 25, 967–971 (2004).

  36. 36.

    , , & Reduced 1α-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 61, 2852–2856 (2001).

  37. 37.

    et al. 25-Hydroxyvitamin D-1 α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J. Steroid Biochem. Mol. Biol. 81, 135–140 (2002).

  38. 38.

    et al. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J. Clin. Endocrinol. Metab. 98, 1498–1507 (2013).

  39. 39.

    et al. Dietary vitamin D3 and 1,25-dihydroxyvitamin D3 (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 153, 2576–2587 (2012).

  40. 40.

    et al. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res. 164, 239–246 (2003).

  41. 41.

    , , & Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1α, 25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res. 1, 997–1003 (1995).

  42. 42.

    , & Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132, 1952–1960 (1993).

  43. 43.

    et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nature Genet. 25, 144–146 (2000).

  44. 44.

    , , & Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J. Urol. 168, 1583–1588 (2002).

  45. 45.

    , , & Liarozole acts synergistically with 1α, 25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140, 2071–2076 (1999).

  46. 46.

    , , & Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D(3) in DU145 human prostate cancer cells: Role of the direct inhibition of CYP24 enzyme activity. Mol. Cell Endocrinol. 12, 12 (2005).

  47. 47.

    , , & Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer. Prostate 72, 1628–1637 (2012).

  48. 48.

    et al. 25-Hydroxyvitamin D(3)-1α-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 66, 287–292 (2001).

  49. 49.

    et al. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 10, 483 (2010).

  50. 50.

    et al. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin. Cancer Res. 11, 3579–3586 (2005).

  51. 51.

    , , , & Targeted disruption of the 25-hydroxyvitamin D3 1α-hydroxylase gene in ras-transformed keratinocytes demonstrates that locally produced 1α, 25-dihydroxyvitamin D3 suppresses growth and induces differentiation in an autocrine fashion. Mol. Cancer Res. 1, 56–67 (2002).

  52. 52.

    et al. Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res. 51, 239–244 (1991).

  53. 53.

    et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J. Clin. Oncol. 29, 2378–2385 (2011).

  54. 54.

    et al. The association between vitamin D receptor expression and prolonged overall survival in breast cancer. J. Histochem. Cytochem. 60, 121–129 (2012).

  55. 55.

    , & Regulation of target gene expression by the vitamin D receptor -an update on mechanisms. Rev. Endocr. Metab. Disord. 13, 45–55 (2012).

  56. 56.

    , , & Vitamin D receptor (VDR)-mediated actions of 1α, 25(OH)2 vitamin D3: genomic and non-genomic mechanisms. Best Pract. Res. Clin. Endocrinol. Metab. 25, 543–559 (2011). Written by experts, this paper discusses both the classical genomic and non-genomic actions of calcitriol and describes the mechanisms underlying these effects.

  57. 57.

    , , & Role of the 1,25D3-MARRS receptor in the 1,25(OH)2D3-stimulated uptake of calcium and phosphate in intestinal cells. Steroids 77, 897–902 (2012).

  58. 58.

    et al. The role of the vitamin D receptor and ERp57 in photoprotection by 1α, 25-dihydroxyvitamin D3. Mol. Endocrinol. 26, 574–582 (2012).

  59. 59.

    , & 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108, 1083–1086 (1981). This is the first study to demonstrate an anticancer effect of calcitriol in cultured cells; it shows that calcitriol inhibited the proliferation of malignant melanoma cells.

  60. 60.

    et al. Differentiation of mouse myeloid leukemia cells induced by 1 α, 25-dihydroxyvitamin D3. Proc. Natl Acad. Sci. USA 78, 4990–4994 (1981). This study, which was published in the same year as reference 59, showed a beneficial differentiating effect of calcitriol on mouse myeloid leukaemia cells, thereby providing evidence that calcitriol had anticancer activity in a second malignancy.

  61. 61.

    & Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr. Relat. Cancer 17, R19–R38 (2010).

  62. 62.

    , , , & Genomic vitamin D signaling in breast cancer: Insights from animal models and human cells. J. Steroid Biochem. Mol. Biol. 121, 362–367 (2010).

  63. 63.

    & Identification of novel mediators of Vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells. J. Steroid Biochem. Mol. Biol. 103, 703–707 (2007).

  64. 64.

    et al. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 59, 243–251 (2004).

  65. 65.

    et al. Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer. Biochem. Pharmacol. 72, 332–343 (2006).

  66. 66.

    et al. Interleukin-1α mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res. 71, 5276–5286 (2011). This study shows the inhibitory actions of vitamin D on cells that might be the prostate cancer stem cells.

  67. 67.

    et al. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J. Steroid Biochem. Mol. Biol. 92, 131–141 (2004).

  68. 68.

    , , , & Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res. Treat. 80, 49–62 (2003).

  69. 69.

    & SNAIL versus vitamin D receptor expression in colon cancer: therapeutics implications. Br. J. Cancer 92, 985–989 (2005).

  70. 70.

    et al. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 151, 32–42 (2010).

  71. 71.

    et al. Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo. Horm. Cancer 2, 190–202 (2011).

  72. 72.

    , , & Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J. Endocrinol. 141, 555–563 (1994).

  73. 73.

    , , , & Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res. Treat. 42, 31–41 (1997).

  74. 74.

    , & 1α, 25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin. Cancer Res. 6, 3371–3379 (2000).

  75. 75.

    , , , & Transrepression of the estrogen receptor promoter by calcitriol in human breast cancer cells via two negative vitamin D response elements. Endocr. Relat. Cancer 20, 565–577 (2013).

  76. 76.

    & The development of androgen-independent prostate cancer. Nature Rev. Cancer 1, 34–45 (2001).

  77. 77.

    & Molecular pathogenesis and progression of prostate cancer. Semin. Oncol. 40, 244–258 (2013).

  78. 78.

    , & Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol. Ther. 140, 223–238 (2013).

  79. 79.

    et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nature Med. 6, 703–706 (2000).

  80. 80.

    , , , & Regulation of growth, PSA/PAP and androgen receptor expression by 1 α, 25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Biochem. Biophys. Res. Commun. 223, 141–146 (1996).

  81. 81.

    , , & Induction of androgen receptor by 1α, 25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140, 1205–1212 (1999).

  82. 82.

    , , & 1α, 25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141, 2548–2556 (2000).

  83. 83.

    et al. Vitamin D and prostate cancer. J. Steroid Biochem. Mol. Biol. 76, 125–134 (2001).

  84. 84.

    , & Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate 64, 362–372 (2005).

  85. 85.

    in National Institutes of Health Report No. 87–2881 (ed. Rodgers, C. H.e.a.) 85–94 (1987).

  86. 86.

    , , & Generation of a prostate from a single adult stem cell. Nature 456, 804–808 (2008).

  87. 87.

    et al. 1α, 25-(OH)2-D3 and its synthetic analogue decrease tumor load in the Apc(min) Mouse. Cancer Res. 62, 741–746 (2002).

  88. 88.

    , , , & Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946–10951 (2005).

  89. 89.

    , , & Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 67, 4807–4815 (2007).

  90. 90.

    et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461, 495–500 (2009).

  91. 91.

    et al. Molecular profiling of human mammary gland links breast cancer risk to a p27+ cell population with progenitor characteristics. Cell Stem Cell 13, 117–130 (2013).

  92. 92.

    et al. Down-regulation of vitamin D receptor in mammospheres: implications for vitamin D resistance in breast cancer and potential for combination therapy. PLoS ONE 8, e53287 (2013).

  93. 93.

    et al. A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol. Pharmacol. 79, 360–367 (2011).

  94. 94.

    , & The long and short of microRNA. Cell 153, 516–519 (2013).

  95. 95.

    et al. Butyrate and vitamin D3 induce transcriptional attenuation at the cyclin D1 locus in colonic carcinoma cells. J. Cell. Physiol. 218, 638–642 (2009).

  96. 96.

    et al. MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum. Mol. Genet. 21, 2157–2165 (2012).

  97. 97.

    et al. Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue. Cancer Prev. Res. 6, 483–494 (2013).

  98. 98.

    , , , & MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res. 71, 6230–6239 (2011).

  99. 99.

    et al. 1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498. J. Biol. Chem. 287, 41297–41309 (2012).

  100. 100.

    , , , & MicroRNA-627 mediates the epigenetic mechanisms of vitamin D to suppress proliferation of human colorectal cancer cells and growth of xenograft tumors in mice. Gastroenterology 145, 437–446 (2013).

  101. 101.

    , , & Identification of microRNA-98 as a therapeutic target inhibiting prostate cancer growth and a biomarker induced by vitamin D. J. Biol. Chem. 288, 1–9 (2013).

  102. 102.

    , , & MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 8, 736–741 (2009).

  103. 103.

    et al. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol. Pharmacol. 76, 702–709 (2009).

  104. 104.

    , , , & MicroRNA regulates human vitamin D receptor. Int. J. Cancer 125, 1328–1333 (2009).

  105. 105.

    , & Vitamin D3 receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis 23, 2103–2109 (2002).

  106. 106.

    et al. Prevention of preneoplastic lesions by dietary vitamin D in a mouse model of colorectal carcinogenesis. J. Steroid Biochem. Mol. Biol. 136, 284–288 (2013).

  107. 107.

    et al. Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis 30, 88–92 (2009).

  108. 108.

    et al. Dietary vitamin D and vitamin D receptor level modulate epithelial cell proliferation and apoptosis in the prostate. Cancer Prev. Res. 4, 1617–1625 (2011).

  109. 109.

    et al. Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine model. Anticancer Res. 32, 727–731 (2012).

  110. 110.

    & Do sunlight and vitamin D reduce the likelihood of colon cancer? Int. J. Epidemiol. 9, 227–231 (1980). This is the first report to link a lack of sunlight exposure to colon cancer risk, which raised the hypothesis that sunlight is a surrogate for vitamin D and that vitamin D deficiency is a risk factor for colon cancer.

  111. 111.

    & Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70, 2861–2869 (1992). This was the first report to link reduced sunlight exposure to increased risk of prostate cancer, which prompted investigations into mechanisms by which vitamin D may protect against cancer risk.

  112. 112.

    Ecological studies of the UVB-vitamin D-cancer hypothesis. Anticancer Res. 32, 223–236 (2012).

  113. 113.

    , , , & Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann. Intern. Med. 155, 827–838 (2011).

  114. 114.

    et al. Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies. Cancer Prev. Res. (Phila) 4, 735–743 (2011).

  115. 115.

    et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 22, 319–340 (2011).

  116. 116.

    , , & Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control 23, 1377–1385 (2012).

  117. 117.

    et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J. Natl Cancer Inst. 100, 1581–1591 (2008).

  118. 118.

    , , & Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. Medicine 92, 123–131 (2013).

  119. 119.

    et al. Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: a nested case-control study. Int. J. Cancer 133, 1689–1700 (2013).

  120. 120.

    et al. Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study. Breast Cancer Res. 15, R15 (2013).

  121. 121.

    et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol. 172, 10–20 (2010).

  122. 122.

    & Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol. 172, 4–9 (2010).

  123. 123.

    et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol. 172, 81–93 (2010).

  124. 124.

    et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 21, 82–91 (2012).

  125. 125.

    , , & Vitamin D status and ill health. Lancet Diabetes and Endocrinol. 2, 76–89 (2014).

  126. 126.

    et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J. Natl. Cancer Inst. 98, 451–459 (2006).

  127. 127.

    et al. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS ONE 6, e18625 (2011).

  128. 128.

    et al. Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiol. Biomarkers Prev. 21, 582–593 (2012).

  129. 129.

    et al. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: A systematic review and meta-analysis. Prev. Med. 57, 753–764 (2013).

  130. 130.

    et al. Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World J. Gastroenterol. 18, 1672–1679 (2012).

  131. 131.

    , , & Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 30, 1170–1180 (2009).

  132. 132.

    et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 20, 1003–1016 (2011).

  133. 133.

    et al. Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol. Biomarkers Prev. 18, 2874–2881 (2009).

  134. 134.

    et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 30, 769–776 (2009).

  135. 135.

    , , & Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol. Biomarkers Prev. 20, 1708–1717 (2011).

  136. 136.

    et al. Vitamin D related genes, CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiol. Biomarkers Prev. 18, 2540–2548 (2009).

  137. 137.

    et al. Common genetic variants in the vitamin D pathway including genome-wide associated variants are not associated with breast cancer risk among Chinese women. Cancer Epidemiol. Biomarkers Prev. 20, 2313–2316 (2011).

  138. 138.

    et al. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol. Biomarkers Prev. 16, 1990–1999 (2007).

  139. 139.

    , , , & Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 18, 1929–1933 (2009).

  140. 140.

    et al. Genetic variation in the vitamin D receptor (VDR) and the vitamin D-binding protein (GC) and risk for colorectal cancer: results from the Colon Cancer Family Registry. Cancer Epidemiol. Biomarkers Prev. 19, 525–536 (2010).

  141. 141.

    et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J. Natl Cancer Inst. 104, 690–699 (2012).

  142. 142.

    et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp. Clin. Trials 33, 159–171 (2012). This is a description of the large, ongoing RCT supported by the US National Institutes of Health (NIH) that will hopefully clarify whether vitamin D intervention will reduce the risk of cancer and other diseases.

  143. 143.

    Uncertain verdict as vitamin D goes on trial. Science 337, 1476–1478 (2012).

  144. 144.

    et al. The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutr. Cancer 63, 827–841 (2011).

  145. 145.

    , & Vitamin D supplementation in young Caucasian and African American women. J. Bone Miner. Res. 29, 173–181 (2013).

  146. 146.

    , , & Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am. J. Clin. Nutr. 94, 1144–1149 (2011).

  147. 147.

    , & Caution in reinterpreting the Women's Health Initiative (WHI) Calcium and Vitamin D Trial breast cancer results. Am. J. Clin. Nutr. 95, 258–259 (2012).

  148. 148.

    , , , & Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr. 85, 1586–1591 (2007).

  149. 149.

    , & Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326, 469 (2003).

  150. 150.

    , , , & A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on the APC/β-catenin pathway in the normal mucosa of colorectal adenoma patients. Cancer Prev. Res. 5, 1247–1256 (2012).

  151. 151.

    et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J. Clin. Endocrinol. Metab. 97, 2670–2681 (2012).

  152. 152.

    et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J. Clin. Endocrinol. Metab. 97, 2315–2324 (2012).

  153. 153.

    , , & 25-hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Arterioscler Thromb. Vasc. Biol. 32, 2794–2802 (2012).

  154. 154.

    et al. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). J. Clin. Endocrinol. Metab. 97, 614–622 (2012).

  155. 155.

    et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst. Rev. 1, CD007470 (2014). This is a huge systematic review of many published studies that was commissioned by the IOM to evaluate the effects of vitamin D on cancer; it concluded that mortality and cancer-related mortality are probably inversely related to 25(OH)D concentrations in blood.

  156. 156.

    , , & Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J. Urol. 159, 2035–2039; discussion 2039–2040 (1998).

  157. 157.

    & Calcitriol in the treatment of prostate cancer. Anticancer Res. 26, 2647–2651 (2006).

  158. 158.

    et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J. Clin. Oncol. 25, 669–674 (2007).

  159. 159.

    et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J. Clin. Oncol. 29, 2191–2198 (2011).

  160. 160.

    , & Phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res. 28, 1611–1626 (2008).

  161. 161.

    et al. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin. Cancer Res. 14, 2437–2443 (2008).

  162. 162.

    et al. Feasibility of a randomized controlled trial of vitamin D versus placebo in women with recently diagnosed breast cancer. Breast Cancer Res. Treat. 134, 759–767 (2012).

  163. 163.

    et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 70, 1448–1460 (2010).

  164. 164.

    et al. IOM committee members respond to Endocrine Society vitamin D guideline. J. Clin. Endocrinol. Metab. 97, 1146–1152 (2012).

  165. 165.

    , , & 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138, 1491–1497 (1997).

  166. 166.

    , , & Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology 151, 896–908 (2010).

  167. 167.

    , , , & Inhibitory effects of 1α, 25-dihydroxyvitamin D3 on the G1-S phase-controlling machinery. Mol. Endocrinol. 15, 1370–1380 (2001).

  168. 168.

    , , , & Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10, 142–153 (1996).

  169. 169.

    , , & Insulin-like growth factor binding protein-3 mediates 1 α, 25-dihydroxyvitamin d3 growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J. Urol. 165, 1319–1324 (2001).

  170. 170.

    , & in Vitamin D (eds Feldman, D., Pike, J. W. & Glorieux, F. H.) 1727–1740 (Elsevier Academic Press, 2005).

  171. 171.

    & 1α, 25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 150, 2046–2054 (2009).

  172. 172.

    et al. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res. 59, 4023–4029 (1999).

  173. 173.

    , , & Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141, 10–17 (2000).

  174. 174.

    et al. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 75, 193–207 (2007).

  175. 175.

    , , & Cancer-related inflammation. Nature 454, 436–444 (2008).

  176. 176.

    et al. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 65, 7917–7925 (2005).

  177. 177.

    , , & Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res. 66, 4516–4524 (2006).

  178. 178.

    , & 1α, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27, 1883–1893 (2006).

  179. 179.

    , , , & Vitamin D decreases NFκB activity by increasing IκBα levels. Nephrol. Dial Transplant 21, 889–897 (2006).

  180. 180.

    , & Down-regulation of NF-κ B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proc. Natl Acad. Sci. USA 92, 10990–10994 (1995).

  181. 181.

    & 1α, 25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 11, 221–229 (2000).

  182. 182.

    , & 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett. 426, 225–228 (1998).

  183. 183.

    & 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol. Cell Endocrinol. 164, 133–143 (2000).

  184. 184.

    , & 1α, 25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 27, 32–42 (2006).

  185. 185.

    , , , & Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, 27kip1 and E-cadherin. J. Mol. Endocrinol. 19, 15–27 (1997).

  186. 186.

    et al. 1α, 25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol. Cancer Ther. 6, 1433–1439 (2007).

  187. 187.

    et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 69, 967–975 (2009).

  188. 188.

    , & Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 63, 2330–2334 (2003).

  189. 189.

    et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376, 180–188 (2010). This genome-wide association study identified SNPs in vitamin D synthesis pathway genes and the DBP carrier protein that are associated with vitamin D deficiency.

  190. 190.

    et al. Genetic variants in vitamin d pathway genes and risk of pancreas cancer; results from a population-based case-control study in ontario, Canada. PLoS ONE 8, e66768 (2013).

  191. 191.

    et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N. Engl. J. Med. 369, 1991–2000 (2013).

  192. 192.

    et al. Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol. Biomarkers Prev. 13, 1325–1330 (2004).

  193. 193.

    et al. Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol. Biomarkers Prev. 12, 23–27 (2003).

  194. 194.

    et al. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 29, 3511–3536 (2009).

  195. 195.

    et al. Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies. BMC Cancer 8, 385 (2008).

  196. 196.

    et al. Vitamin D receptor genotype rs731236 (Taq1) and breast cancer prognosis. Cancer Epidemiol. Biomarkers Prev. 22, 437–442 (2013).

  197. 197.

    et al. Polymorphisms related to the serum 25-hydroxyvitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromsø Study. PLoS ONE 7, e37295 (2012).

  198. 198.

    et al. Modification of the inverse association between dietary vitamin D intake and colorectal cancer risk by a FokI variant supports a chemoprotective action of Vitamin D intake mediated through VDR binding. Int. J. Cancer 123, 2170–2179 (2008).

  199. 199.

    et al. Genetic variation in the vitamin d pathway in relation to risk of prostate cancer—results from the breast and prostate cancer cohort consortium. Cancer Epidemiol. Biomarkers Prev. 22, 688–696 (2013).

Download references

Acknowledgements

D.F. acknowledges research grant support from California Breast Cancer Research Program, the American Institute for Cancer Research and the Department of Defense Breast and Prostate Cancer Research Programs. B.J.F. is supported by a US National Institutes of Health (NIH) Director's New Innovator Award (DP2OD006740) and the California Breast Cancer Research Program.

Author information

Affiliations

  1. Department of Medicine, Division of Endocrinology, Stanford University School of Medicine, Stanford, California 94305, USA.

    • David Feldman
    • , Aruna V. Krishnan
    •  & Srilatha Swami
  2. Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA.

    • Edward Giovannucci
  3. Department of Pediatrics, Division of Pediatric Endocrinology, Stanford University School of Medicine, Stanford, California 94305, USA.

    • Brian J. Feldman

Authors

  1. Search for David Feldman in:

  2. Search for Aruna V. Krishnan in:

  3. Search for Srilatha Swami in:

  4. Search for Edward Giovannucci in:

  5. Search for Brian J. Feldman in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to David Feldman.

Supplementary information

PDF files

  1. 1.

    Supplementary information S1 (figure)

    Vitamin D synthesis and degradation

  2. 2.

    Supplementary information S2 (box)

    The cancer stem cell hypothesis

  3. 3.

    Supplementary information S3 (table)

    Tumor inhibitory effects of calcitriol and vitamin D in animal models

Glossary

Randomized clinical trials

(RCTs). Trials in humans that are the gold standard for proof of efficacy of an intervention in cancer and other diseases.

Hypercalcaemia

Increased levels of blood calcium that can lead to many symptoms, including muscle cramps, drowsiness, bone pain, kidney stones and, in severe cases, cardiac arrest and coma.

Calciotropic hormones

A complex network of hormones that regulates calcium and phosphate metabolism to normalize bone mineralization, including calcitriol, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23).

Prostate-specific antigen

(PSA). A useful biomarker for prostate growth, especially to monitor the recurrence of prostate cancer.

Naproxen

An anti-inflammatory drug that inhibits cyclooxygenase 2 (COX2), which is the rate-limiting enzyme that catalyses prostaglandin synthesis.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrc3691